Epigallocatechin Gallate in Progressive MS: A Randomized, Placebo-Controlled Trial.
Rebekka RustClaudia ChienMichael ScheelAlexander Ulrich BrandtJan DörrJens WuerfelKatharina KlumbiesHanna ZimmermannMario LorenzKlaus-Dieter WerneckeJudith Bellmann-StroblFriedemann PaulPublished in: Neurology(R) neuroimmunology & neuroinflammation (2021)
This phase II trial provides Class II evidence that for patients with PMS, EGCG was safe, well tolerated, and did not significantly reduce the rate of brain atrophy.